Skip to main content

Table 5 Influence of APOE genotypes on serum lipids in hypercholesterolemic individuals treated with atorvastatin (10 mg/day/4-weeks)

From: Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin

Parameter

 

ε2 (5)

ε3 (92)

ε4 (44)

p-value

Total cholesterol,

Basal

253 ± 25

284 ± 39

275 ± 27

0.100

mg/dL

Treatment

174 ± 28

198 ± 31

198 ± 27

0.285

 

Change, %

-32 ± 6

-30 ± 10

-28 ± 8

0.332

LDL cholesterol,

Basal

166 ± 22

194 ± 37

188 ± 21

0.166

mg/dL

Treatment

96 ± 20

116 ± 28

119 ± 22

0.262

 

Change, %

-42 ± 9

-40 ± 13

-37 ± 10

0.408

HDL cholesterol,

Basal

62 ± 18

57 ± 15

55 ± 11

0.534

mg/dL

Treatment

55 ± 14

55 ± 14

53 ± 10

0.745

 

Change, %

-11 ± 11

-3 ± 11

-3 ± 9

0.270

VLDL cholesterol,

Basal

27 ± 8

32 ± 14

31 ± 11

0.672

mg/dL

Treatment

24 ± 12

26 ± 12

26 ± 9

0.880

 

Change, %

-10 ± 38

-14 ± 30

-12 ± 25

0.902

Triglycerides,

Basal

133 ± 42

159 ± 72

155 ± 53

0.672

mg/dL

Treatment

118 ± 58

130 ± 58

131 ± 43

0.880

 

Change, %

-10 ± 38

-14 ± 30

-12 ± 25

0.902

ApoAI,

Basal

140 ± 34

138 ± 29

132 ± 19

0.418

mg/dL

Treatment

151 ± 54

140 ± 28

133 ± 24

0.259

 

Change, %

+6 ± 16

+2 ± 11

+1 ± 13

0.650

ApoB,

Basal

128 ± 29

143 ± 28

143 ± 25

0.532

mg/dL

Treatment

97 ± 23

99 ± 21

97 ± 19

0.984

 

Change, %

-24 ± 7

-30 ± 13

-31 ± 11

0.494

  1. Number of individuals is in parenthesis. -/+ symbols in change indicate reduction or increment of each parameter. Values are presented as media ± SD and compared by one way ANOVA. LDL, low density lipoprotein; HDL, high density lipoprotein; VLDL, very low density lipoprotein. ε2 : ε2ε2 and ε2ε3 genotypes; ε3: ε3ε3 genotype; ε4: ε3ε4 and ε4ε4 genotypes. Conversion factors to convert to Systeme Internacional (SI) units are 0.02586 for cholesterol (mmol/l), 0.01129 for triglycerides (mmol/l) and 0.01 for apolipoproteins (g/l).